Now Playing
|Videos|August 29, 2022
Available Molecular Tests for Solid Tumors
Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.
Episodes in this series
Related to this article
Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.
Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.
The FDA has granted fast track designation to varsetatug masetecan for relapsed/refractory metastatic colorectal cancer.
SYS6090, a first-in-class PD-1/IL-15 bispecific fusion protein, earned fast track status for MSS/pMMR metastatic colorectal cancer that has progressed on standard systemic therapy.
Cathy Eng, MD, FACP, FASCO, discusses how oncology fellows can navigate the journal submission and review process.
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
Trending on OncLive
1
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
2
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Borate on Efficacy Data for Shorter Venetoclax-Plus-Azacitidine Dosing in AML
5